Klaus Vedfelt/DigitalVision via Getty Images
Goldman Sachs has started Teladoc Health (NYSE:TDOC) off at buy saying that the telehealth provider is poised to benefit from revenue and membership growth, particularly starting in 2026.
The firm has a $14 price target (~56% upside based on Nov. 14 close).